Galapagos increases share capital through warrant exercises

Galapagos increases share capital through warrant exercises 
MECHELEN, BELGIUM -- (Marketwired) -- 04/08/13 --  
Mechelen, Belgium; 8 April 2013 - Galapagos NV (Euronext: GLPG)
announced today a capital increase arising from employee warrant
Since its inception in 1999, Galapagos has used warrant plans to
incentivize personnel and management and have them share in the
success of the company. Following warrant exercises during the
exercise period from 9 March 2013 through 29 March 2013, Galapagos
issued 197,581 new ordinary shares on 5 April 2013 for a total
capital increase (including issuance premium) of EUR1,181,926.39. 
CEO Onno van de Stolpe exercised 50,000 warrants, granted in 2008 and
which were due to expire on 25 June 2013. Of these, 20,000 were
exercised through a cashless exercise facility to finance the cash
exercise of 30,000 warrants. Onno van de Stolpe's shareholding in
Galapagos thereby increased by 30,000 shares to a total of 355,448
shares, or 1.32% of the outstanding Galapagos shares. 
To date, Galapagos' total share capital amounts to EUR145,884,501.48;
the total number of securities conferring voting rights is 26,968,328,
which is also the total number of voting rights (the "denominator"),
and all securities conferring voting rights and all voting rights are
of the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
3,123,368, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have
any convertible bonds or shares without voting rights outstanding. 
About Galapagos 
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of- action, with a large pipeline of four clinical, six
pre-clinical, and 30 discovery small-molecule and antibody programs
in cystic fibrosis, inflammation, antibiotics, metabolic disease, and
other indications. GLPG0634 is an orally-available, selective
inhibitor of JAK1 for the treatment of rheumatoid arthritis and
potentially other inflammatory diseases, about to enter Phase 2b
studies. AbbVie and Galapagos signed a worldwide license agreement
whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective
JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184
(formerly GLPG0778, in- licensed by GlaxoSmithKline in 2012).
GLPG0187 is a novel integrin receptor antagonist currently in a Phase
1b patient study in metastasis. GLPG0974 is the first inhibitor of
FFA2 to be evaluated clinically for the treatment of IBD; this
program will start a Proof of Concept Phase 2 study in Q2 2013. The
Galapagos Group, including fee-for- service companies BioFocus,
Argenta and Fidelta, has around 800 employees and operates facilities
in five countries, with global headquarters in Mechelen, Belgium.
Further information at: 
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward- looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the date
of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation. 
Galapagos increases share capital through warrant exercises: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein. 
Source: Galapagos NV via Thomson Reuters ONE [HUG#1691280] 
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Press spacebar to pause and continue. Press esc to stop.